Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Studies suggest that IGF-1 LR3 might activate key signaling pathways, including the phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) cascades, both of which are central to cellular proliferation and survival
You won't start on the full dose right away
Variants of OXM resistant to DPP-IV (achieved by addition of PEG [86], fatty acids [87], substitution of certain amino acids [85] or even combined modifications [88]) have been advanced to circumvent the limited clinical potential of the native peptide
Weekly dosing, predictable absorption, and a well-documented safety history are the main reasons most patients and physicians default to it
Novartis: Bimagrumab/BYM338 Bimagrumab is an antibody against activin type II receptor (ActRII) meaning that it acts as an ActRII antagonist (It prevents ActRII from functioning)
US$ 28.77
US$ 21.34
US$ 20.52
US$ 25.89
US$ 22.50
US$ 27.72
US$ 27.06
